Docetaxel News and Research

RSS
Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

Oncolytics completes Phase II trial enrollment for REOLYSIN in prostate cancer

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab may change treatment strategies for refractory lung cancer patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Nivolumab drug improves survival for non-SQ NSCLC patients

AstraZeneca presents lung cancer research data at WCLC 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Enrollment completed for REOLYSIN Phase II study in patients with advanced or metastatic NSCLC

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

Clinical study shows two-drug combination can prolong survival in men with metastatic prostate cancer

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

Phase 3 SUMIT study: Selumetinib fails to meet primary endpoint in patients with metastatic uveal melanoma

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

OncoGenex's custirsen Phase 3 ENSPIRIT trial for treatment of NSCLC patients continues as planned

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Elsevier, NCI implement two-way linking between research articles on ScienceDirect and datasets in caNanoLab

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

Spotting the symptoms of advanced prostate cancer: an interview with Brian Tomlinson

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Study explores role of ALK1 protein in breast cancer metastasis

Study explores role of ALK1 protein in breast cancer metastasis

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

Advanced prostate cancer patients who have AR-V7 gene variant respond to chemotherapy

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

CheckMate for nivolumab in untreated melanoma, squamous NSCLC

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients

Apatorsen added to first-line chemotherapy benefits metastatic bladder cancer patients